Company attributes
Industry
Location
CEO
AngelList URL
Pitchbook URL
Legal Name
InflaRx N.V.
Number of Employees (Ranges)
51 – 200
Email Address
info@inflarx.de0
Phone Number
+4936415081800
+498941418978000
Full Address
Winzerlaer Str. 2 07745 Jena0
Fraunhoferstraße 22 82152 Martinsried0
CIK Number
Place of Incorporation
Investors
Founded Date
December 2007
0Total Funding Amount (USD)
55,000,000
Latest Funding Round Date
October 2017
Stock Symbol
IFRX
Exchange
Board of Directors
CFO
Latest Funding Type
Patents Assigned (Count)
1
Wellfound ID
Country
Other attributes
Company Operating Status
Active
Contact Page URL
Previous Name
Fireman B.V.0
SIC Code
2,8340
Ticker Symbol
IFRX
Vision
InflaRx Vision and Strategy
InflaRx is focused on developing its proprietary anti-C5a technology while broadening and diversifying the R&D pipeline. Specifically, InflaRx will:
- Continue to development of our anti-C5a technology with Vilobelimab
- Hidradenitis Suppurativa: Initiate Phase III program incorporating novel endpoint
- Pyoderma Gangrenosum: Advance towards Phase III based on regulatory guidance
- Severe COVID-19: Complete Phase III and submit for approval if results are positive
- Anca-Associated Vasculitis: Discuss next steps with regulatory authorities
- Oncology: Continue to explore clinical applications
- Advance INF904 into first-in-human studies
- Continue to explore broadening the R&D pipeline beyond anti-C5a technology as part of a diversification strategy
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
